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1  | INTRODUC TION
Since its emergence in December 2019, the coronavirus disease 2019 
(COVID-19), caused by severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2), has had a devastating global health impact.1 COVID-
19 is associated with a high incidence of multiorgan dysfunction and 
mortality.2,3 Accordingly, there has been an extraordinary response by 
the international research community to quickly develop trials to eval-
uate potential disease-modifying interventions in COVID-19.
Early in the COVID-19 pandemic, several reports described hy-
pertension as a risk factor for SARS-CoV-2 infection and severity.4 
Angiotensin-converting enzyme 2 (ACE2), a key counterregulatory 
component of the renin-angiotensin system (Figure 1), plays an 
important role in hypertension pathophysiology and also facilitates 
SARS-CoV-2 host cell entry.5 ACE2 activity and expression have 
been implicated as potential contributors to SARS-CoV-2 infection 
and severity.4 Angiotensin-converting enzyme inhibitors (ACEIs) and 
angiotensin receptor blockers (ARBs), two of the most commonly 
used antihypertensive classes,6 may increase ACE2 expression.4 
Consequently, it was speculated that ACEIs and ARBs could worsen 
the risk of COVID-19 and COVID-19-related adverse outcomes,7-10 
resulting in widespread media coverage and possibly in empiric dis-
continuation of these medications. However, there is also evidence 
suggesting that ACE2 overexpression ameliorates lung injury asso-
ciated with COVID-19,11,12 and thus, ACEIs and ARBs could reduce 
adverse outcomes in patients with this infection.4 Thus, it remains 
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Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus respon-
sible for coronavirus disease 2019 (COVID-19), is associated with high incidence of 
multiorgan dysfunction and death. Angiotensin-converting enzyme 2 (ACE2), which 
facilitates SARS-CoV-2 host cell entry, may be impacted by angiotensin-converting 
enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), two commonly 
used antihypertensive classes. In a multicenter, international randomized controlled 
trial that began enrollment on March 31, 2020, participants are randomized to contin-
uation vs withdrawal of their long-term outpatient ACEI or ARB upon hospitalization 
with COVID-19. The primary outcome is a hierarchical global rank score incorporating 
time to death, duration of mechanical ventilation, duration of renal replacement or 
vasopressor therapy, and multiorgan dysfunction severity. Approval for the study has 
been obtained from the Institutional Review Board of each participating institution, 
and all participants will provide informed consent. A data safety monitoring board has 
been assembled to provide independent oversight of the project.
F I G U R E  1   The counterregulatory 
role of ACE2 in the renin-angiotensin 
system. Angiotensin-converting enzyme 
inhibitors and angiotensin receptor 
blockers may increase ACE2 levels. This 
effect is speculated to increase the risk 
of SARS-CoV-2 host cell entry but may 
also have important anti-inflammatory 
effects
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unclear whether ACEIs and ARBs are beneficial or harmful in pa-
tients with COVID-19.
Given the high prevalence of ACEI and ARB use in the general pop-
ulation and the potential for harm by inappropriate discontinuation of 
these medications due to their cardio- and reno-protective effects,6 it 
is critical to better understand the appropriate acute management of 
patients with COVID-19 who use ACEIs and ARBs for the long-term 
management of chronic conditions. Thus, we aimed to perform a ran-
domized controlled trial to evaluate the effect of continuation compared 
with discontinuation of ACEIs and ARBs on hospitalization-related out-
comes in patients admitted with COVID-19. We developed a hierarchi-
cal composite end point of outcomes with public health, clinical, and 
patient-centered significance using a global rank score.
2  | METHODS AND ANALYSIS
2.1 | Overview of the trial design
Figure 2 illustrates the study structure and design. The Randomized 
Elimination or ProLongation of ACEIs and ARBs in COronaVIrus 
Disease 2019 trial (REPLACE COVID: NCT04338009) is a prospec-
tive randomized open-label blinded end point (PROBE) trial13 of 
continuation vs discontinuation of ACEI/ARB therapy in patients 
admitted to the hospital with COVID-19. The primary end point is a 
novel hierarchical global rank score including time to death, duration 
of mechanical ventilation, duration of renal replacement therapy or 
vasopressor therapy, and measures of multiorgan dysfunction.
Participants are being recruited upon admission to the hospital 
with COVID-19 at participating centers in the United States, Canada, 
Mexico, Argentina, Peru, Bolivia, and Sweden (Figure 3). The trial was 
approved by the Institutional Review Board or the Ethics Committee 
of each participating center, or via reliance agreements with the 
Institutional Review Board at the University of Pennsylvania, which 
is serving as the central Institutional Review Board. All participants 
provided informed consent either in written form or electronically. 
Enrollment started on March 31, 2020, and will continue until 152 
participants have been enrolled.
Participants are randomized to continuation or withdrawal of 
their outpatient ACEI or ARB for the duration of their hospitalization. 
Candidates are excluded if they have a major contraindication to either 
continuing or withdrawing their ACEI or ARB. Participants are followed 
until the end of their hospitalization and are contacted 28 days following 
discharge to assess for any changes in their clinical status after discharge.
2.2 | Hypothesis
Based on currently available information, there is clinical equipoise 
regarding the effect of continuation vs discontinuation of ACEIs and 
F I G U R E  2   Study overview and design
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ARBs in the setting of COVID-19. In some experimental models, 
ACEIs and ARBs increase ACE2 expression in several organs.14-17 
This could potentially lead to increased SARS-CoV-2 virulence, in-
creasing the risk of multiorgan dysfunction and death. However, 
these findings are not consistent across studies18-20 and have not 
been corroborated in humans.21,22 Alternatively, animal models of 
SARS-CoV-1 infection (a virus highly related to SARS-CoV-2) sug-
gest that overexpression of ACE2 protects against lung injury associ-
ated with these infections.11,12 Thus, ACEIs and ARBs may improve 
mechanisms of host defense or hyperinflammation, ultimately re-
ducing organ injury and providing direct renal and cardiac protective 
benefits.12 Observational studies evaluating the association of ACEI 
and ARB use with COVID-19-related outcomes have demonstrated 
mixed results. These studies are highly prone to confounding by in-
dication for continuation or withdrawal of these medications based 
on severity of presentation.23 Additionally, these studies have not 
fully addressed important issues with immortal time bias and collider 
bias.24 A randomized controlled trial is necessary to adequately ad-
dress these important limitations.
2.3 | Participants
Patients are eligible for inclusion in the REPLACE COVID trial if they 
are age 18 years or older at the time of their index hospitalization 
with a clinical presentation consistent with COVID-19. Individuals 
are excluded if they have negative SARS-CoV-2 testing (among 
persons under investigation based on clinical suspicion) or clinical 
contraindications to continuing or withdrawing ACEI or ARB therapy 
including (1) systolic blood pressure <100 mm Hg; (2) systolic blood 
pressure >180 mm Hg or >160 if unable to substitute the ACEI or 
ARB with another antihypertensive class; (3) diastolic blood pres-
sure >110 mm Hg; (4) history of heart failure with unknown left 
ventricular ejection fraction (LVEF) or known LVEF <40%; (5) serum 
potassium >5 mEq/L; (6) known pregnancy or breastfeeding; (7) 
estimated glomerular filtration rate <30 mL/min/1.73 m2; (8) acute 
kidney injury defined as ≥100% increase in creatinine (and a creati-
nine >2 mg/dL) compared with the most recent creatinine in the past 
6 months, if available; (9) urine protein-to-creatinine ratio >3 g/g or 
>3 g/24-hours within the past year; or (10) ongoing treatment with 
F I G U R E  3   Geographic distribution of study sites enrolling participants in the REPLACE COVID trial. As of August 10, 2020, 136 
participants have been enrolled across sites in the United States, Canada, Mexico, Peru, Argentina, Bolivia, and Sweden. Additional sites in 
the United States and Brazil are initiating enrollment
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aliskiren or sacubitril-valsartan. Prisoners are also excluded from 
the trial. Potential participants are typically approached in the first 
48 hours of admission unless they develop COVID-19 during an ad-
mission for another cause.
2.4 | Intervention
The randomized intervention is the continuation compared with 
discontinuation of ACEI or ARB therapy (at the dose previously 
prescribed for patients during their routine care) for the duration 
of the hospitalization. Among participants randomized to continue 
these agents, clinicians are encouraged to continue the randomized 
treatment but are permitted to change the dose of ACEI or ARB or 
to discontinue these medications if a compelling clinical reason is 
identified, such as hypotension, hyperkalemia, or significant acute 
kidney injury. If a participant is prescribed both an ACEI and an 
ARB prior to admission (anticipated to be rare), that individual will 
be randomized to continuation of one or both medications, at the 
clinician's discretion, or discontinuation of both medications. In all 
participants randomized to discontinuation, treating clinicians are 
reminded about the medication discontinuation upon discharge and 
are prompted to consider reinitiating the medication at that time, if 
clinically appropriate.
2.5 | Randomization and blinding
Participants are randomized after providing informed consent either 
in writing or electronically. We are performing stratified blocked 
randomization with randomly permuted blocks based on site, sex, 
and age, given the strong impact of these factors on outcomes in 
COVID-19.3 Each block contains an equal number of allocations to 
each arm. When the patient is randomized, the study team commu-
nicates the randomized treatment strategy to the primary clinician 
and any relevant consultants.
As in other PROBE trials,13 treatment allocation is open, with 
blinding incorporated instead at the level of end point adjudication. 
A clinician panel at each site is appointed to perform blinded adju-
dications of the outcome events. Adjudications are performed using 
a standardized approach to masking patient records so that the cli-
nicians are fully blinded to the randomization arm but are able to 
assess other key aspects of the participants’ hospitalizations.
2.6 | Primary outcome
The primary end point of the trial is a hierarchical global rank 
score, illustrated in Figure 4. The global rank score is a nonpara-
metric ranked outcome that will be determined at the time of dis-
charge or death. The hierarchical end point approach has been 
used in several randomized controlled trials to facilitate evalu-
ation of composite outcomes of binary and continuous findings 
accounting for both the importance of and appropriate censor-
ship for death.25-29 An important benefit of the hierarchical end 
point is that it provides substantially higher statistical power for 
any given sample size compared with other commonly used ap-
proaches, such as 28-day ventilator-free days, time to death, and 
the World Health Organization COVID-19 ordinal end point.30-34 
The outcome of each patient in the REPLACE COVID trial is ranked 
against all other participants from worst to best by increasing val-
ues of (1) days to death during the hospitalization (ordered lowest 
F I G U R E  4   The REPLACE COVID 
global rank score. Participants are ranked 
from worst to best outcomes by (1) days 
in hospital to death; (2) days on invasive 
mechanical ventilation or extracorporeal 
membrane oxygenation; (3) days on 
renal replacement therapy or inotropic/
vasopressor therapy; and (4) area under 
the curve of a modified SOFA score
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to highest); followed by (2) days on invasive mechanical ventila-
tion or extracorporeal membrane oxygenation (ordered highest to 
lowest); followed by (3) days on renal replacement therapy or ino-
tropic/vasopressor therapy (ordered highest to lowest); followed 
by (4) area under the curve of a modified Sequential Organ Failure 
Assessment (SOFA) score.
The modified SOFA score includes the cardiac, respiratory, 
coagulation, and renal domains of the SOFA score (Table S1). A 
modified SOFA score is used, rather than the full SOFA score, as 
the last tier of the global rank score. This decision confers several 
advantages: (1) The cardiac, renal, respiratory, and coagulation 
systems are those most likely impacted by our randomized inter-
vention5,14-17,35; (2) these SOFA components can be easily and reli-
ably adjudicated using electronic health record review, minimizing 
workload on the clinical team and maximizing the pragmatic na-
ture of the trial; and (3) the nervous system (Glasgow comma scale) 
and liver (serum bilirubin) components of the SOFA score are not 
acquired daily on a routine basis in hospitalized patients in non-
ICU settings. For the respiratory component of the SOFA score, 
we are applying a modified score used in settings where arterial 
oxygen saturation is not consistently available,36 which uses pe-
ripheral capillary oxygen saturation instead of arterial oxygen sat-
uration. Use of the modified SOFA score allows all patients in the 
trial to be compared, even when no major adverse events occur. 
We will weight the modified SOFA score to account for duration 
of hospitalization.
In summary, we selected a hierarchical global rank score due to 
its ability to incorporate biomarkers and important clinical events 
into a combined, readily interpretable, and reproducible metric.26,27 
Our proposed global rank score incorporates patient-centered fac-
tors and health resource utilization, while better resolving the time 
course of COVID-19-related events and with higher statistical power 
for any given sample size compared with incorporating each individ-
ual factor.30-34
2.7 | Secondary outcomes
Secondary end points are (1) time to all-cause death; (2) length of 
hospital stay; (3) length of intensive care unit stay, invasive me-
chanical ventilation, or extracorporeal membrane oxygenation; and 
(4) area under the curve of the modified SOFA score, weighted to 
account for death and duration of hospitalization. Exploratory end 
points include (1) intensive care unit admission or respiratory fail-
ure requiring mechanical ventilation; (2) hypotension requiring va-
sopressors, inotropes, or mechanical hemodynamic support such as 
a ventricular assist device or intra-aortic balloon pump; (3) number 
of 28-day ventilator-free days; (4) maximal change in NT-proB-type 
natriuretic peptide from baseline (when available); (5) change in 
serum creatinine between baseline and discharge or time of death; 
(6) acute kidney injury during hospitalization (defined as Kidney 
Disease Improving Global Outcomes stage 2 or higher).37 Additional 
exploratory outcomes will be ascertained by a follow-up call 28 days 
after discharge from the index hospitalization and will include (1) re-
admissions, (2) major adverse cardiac events, (3) functional status, 
and (4) quality of life.
2.8 | Statistical analysis plan
The global rank score is a nonparametric ranked outcome.25-27 The 
primary analyses will be performed on an intent-to-treat basis using 
the total number of participants randomized. Initial descriptive es-
timates of all measures will be generated for study participants by 
randomization arm. Primary assessment of the treatment effect will 
be performed using the nonparametric Wilcoxon rank-sum test. This 
will be followed by a more comprehensive linear regression analysis 
allowing for assessments of the treatment effect while controlling 
for effects of age, sex, race/ethnicity, history of preexisting heart 
failure, history of preexisting chronic lung disease, and ACEI vs ARB 
therapy at baseline.3,38-40 We will utilize nonparametric methods 
or consider distribution-stabilizing transformations, as appropriate. 
The models will include data from participants who drop out.41-43 
Model assumptions will be examined (eg, QQ plots to assess nor-
mally distributed residuals for valid Wald tests). Secondary and 
exploratory time-to-event outcomes will be evaluated using Cox 
proportional hazards models. The proportional hazards assumption 
will be assessed via weighted versions of Kaplan-Meier curves using 
log-log plots and graphical displays based on the Schoenfeld and 
scaled Schoenfeld residuals, and violations of the proportional haz-
ards assumption will be addressed with a time-interaction term.44 In 
exploratory analyses, we will assess for effect modification by sex, 
age,3,38 race,39 presence of preexisting heart failure or left ventricu-
lar dysfunction, baseline ACEI vs ARB therapy,40 chronic kidney dis-
ease, diabetes, and BMI.
We will make every possible effort to minimize missing data and 
ensure final assessments for participants opting to discontinue study 
participation. Missing data, however, are an inevitable problem in 
any study. The mechanism for missingness will be evaluated prior 
to implementing methodology intended to minimize bias from miss-
ing data, such as multiple imputation.45 We anticipate that <5% of 
randomized participants will have missing data in the components 
required to compute the study outcomes.
There is a possibility of systematic bias in the outcomes for those 
who withdraw from the study or crossover treatment arms. In par-
ticipants randomized to continuation of these drugs, clinicians will 
be encouraged to continue the randomized treatment but will be 
allowed to change the dose of ACEI/ARB or discontinue these med-
ications if compelling clinical reasons are identified. As noted above, 
in participants randomized to discontinuation, treating clinicians will 
be reminded about the medication discontinuation upon discharge 
and will be prompted to consider reinitiating the medication at that 
time if appropriate, per the clinician's discretion. Sensitivity analyses 
will be performed on a modified intent-to-treat basis, including only 
data obtained during the period of time in which participants remain 
on the randomized treatment strategy.
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In order to summarize the SOFA score over the course of the hos-
pitalization, we will calculate the area under the curve of the mod-
ified SOFA (AUC SOFA) from daily measurements. The AUC SOFA 
will be ranked from highest to lowest so that lower ranks represent 
worse outcomes in alignment with the rest of the global rank score.
2.9 | Sample size
Assuming feasible distributions of patients across each of the pri-
mary end point hierarchies based on the available published evi-
dence at the time of trial inception,1-3 we performed 10 000 Monte 
Carlo simulations of rank distributions of 152 patients and deter-
mined that there will be >80% power to observe a minimal signifi-
cant difference of 30% in rank scores between the treatment arms, 
allowing for interim analyses at 50% of enrollment.46,47 Regarding 
secondary end points, we will have 90% power to detect a 2-day 
difference in length of ICU stay and length of hospital stay assum-
ing a standard deviation of 2 days based on data from initial reports 
of these outcomes in COVID-19.1-3,32 Power calculations were per-
formed using python and PASS16.48
2.10 | Data management
The University of Pennsylvania is the Data Coordinating Center 
(DCC) for the study. The DCC is overseeing randomization, data 
entry, and data safety monitoring board (DSMB) meetings. The data 
are being collected using ad hoc electronic case report forms. Data 
capture and storage are being performed within the framework of 
the Research Electronic Data Capture (REDCap) project.
2.11 | Data Safety Monitoring Board
A DSMB was assembled to provide independent oversight of the 
project. The DSMB is responsible for assessing (1) baseline compa-
rability between groups; (2) participant accrual rate and retention; 
(3) data quality with special emphasis on eligibility data; and (4) pa-
tient safety. The DSMB will make recommendations regarding study 
continuation, protocol modification, and review of additional data. 
The DSMB reviewed planned interim analyses that were performed 
when the study reached 50% of enrollment. The DSMB also reviews 
new and emerging data related to the proposed trial that would po-
tentially affect the continuation of the trial.
2.12 | Ethics and protection of participants
All partcipants will be adults able to give informed consent or in 
whom informed consent can be obtained by a legally authorized 
representative. Persons will be enrolled regardless of sex, race, or 
ethnicity, aiming to assure adequate representation of women and 
African Americans. Vulnerable populations such as children, preg-
nant women, and prisoners will not be enrolled. The risks to study 
participants are related to the clinical equipoise itself: It is possible 
that one strategy is better than the other, but at the moment this 
clinical equipoise is not solvable based on clinical grounds or intui-
tion. Furthermore, after the initial randomized strategy, our trial al-
lows for altering the course of therapy based on clinical grounds that 
clearly favor one strategy based on clinical assessment as per the 
treating clinician (such as hypotension, which would prompt discon-
tinuation of ACEIs/ARBs among patients randomized to continued 
therapy, or pre-discharge reinitiation of these medications for com-
pelling indications, particularly in the setting of heart failure with a 
reduced ejection fraction).
The cardiovascular risk of short-term ACEI or ARB withdrawal 
is generally minimal. Even in higher risk groups, such as patients 
with moderately decompensated heart failure (NYHA classes II to 
III), heart failure decompensation is not observed until 4-6 weeks 
following ACEI/ARB withdrawal.49 This time course far exceeds the 
typical duration of COVID-19 hospitalization. However, to ensure 
an even higher safety threshold, we created an additional exclusion 
criterion for patients with a LVEF <40%. Patients with heart failure 
and moderately reduced ejection fraction (LVEF 40%-50%) should 
be even less likely to decompensate from ACEI/ARB withdrawal. 
Furthermore, we are reminding treating clinicians of the potential 
need to reinitiate therapy at the time of hospital discharge. In pa-
tients without heart failure, including those with resistant hyperten-
sion, short-term withdrawal of antihypertensive medications is safe 
and well-tolerated.50 To ensure an additional margin of safety for 
this group, we created additional exclusion criteria for patients with 
a baseline systolic blood pressure >180 mm Hg or >160 if unable 
to substitute another drug class in place of ACEIs or ARBs, and for 
diastolic blood pressure ≥110 mm Hg.
In order to minimize exposure of the study staff to COVID-19, 
many sites are using electronic informed consent forms. When elec-
tronic informed consent is performed, potential participants receive 
the consent form via email and provide consent attestation using a 
deidentified participant number via an electronic REDCap survey. 
The informed consent process is performed via phone or video con-
ferencing. The study intervention and potential associated risks are 
explained to study participants verbally, and they have adequate 
time to ask questions. No study interventions are initiated until 
the study team receives either the signed informed consent form 
or attestation documenting the participants’ agreement to partici-
pate. Participants either receive a copy of the signed document via 
email or a REDCap attestation verification email once they agree to 
participate.
2.13 | Regulatory standards
Because the REPLACE COVID trial is not aimed at obtaining regu-
latory approval of a novel drug, a labeled approved indication, or 
repurposing of existing drugs, this trial was formally determined 
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by the Investigational New Drug support unit at the University of 
Pennsylvania to not require a US Food and Drug Administration 
Investigational New Drug application.
2.14 | Current progress
As of August 10, 2020, the study has enrolled 136 of the planned 
152 participants across twelve sites in the United States, Canada, 
Mexico, Peru, Argentina, Bolivia, and Sweden.
2.15 | Trial registration
The trial was registered at ClinicalTrials.gov (NCT04338009).
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